Repository logo
 
Loading...
Profile Picture
Person

Majoral, Jean Pierre

Search Results

Now showing 1 - 2 of 2
  • Morpholino-functionalized phosphorus dendrimers for precision regenerative medicine: osteogenic differentiation of mesenchymal stem cells
    Publication . Li, Aijun; Fan, Yu; Cao, Xueyan; Chen, Liang; Wang, Le; Alves, Carla S.; Mignani, Serge; Majoral, Jean Pierre; Tomás, Helena; Shi, Xiangyang
    A novel bioactive macromolecule based on morpholino-functiona lized phosphorus dendrimers (generation 2, G2-Mor+ ) was devel oped for osteogenic differentiation of mesenchymal stem cells (MSCs). Interestingly, through in vitro tests, it was shown that G2- Mor+ dendrimer can strongly promote the transformation of MSCs into osteoblasts, which implies the potential application of phos phorus de medicine.
  • Dendrimers toward translational nanotherapeutics: concise key step analysis
    Publication . Mignani, Serge; Shi, Xiangyang; Rodrigues, João; Roy, René; Muñoz-Fernández, Ángeles; Ceña, Valentin; Majoral, Jean Pierre
    The goal of nanomedicine is to address specific clinical problems optimally, to fight human diseases, and to find clinical relevance to change clinical practice. Nanomedicine is poised to revolutionize medicine via the development of more precise diagnostic and therapeutic tools. The field of nanomedicine encompasses numerous features and therapeutic disciplines. A plethora of nanomolecular structures have been engineered and developed for therapeutic applications based on their multitasking abilities and the wide functionalization of their core scaffolds and surface groups. Within nanoparticles used for nanomedicine, dendrimers as well polymers have demonstrated strong potential as nanocarriers, therapeutic agents, and imaging contrast agents. In this review, we present and discuss the different criteria and parameters to be addressed to prepare and develop druggable nanoparticles in general and dendrimers in particular. We also describe the major requirements, included in the preclinical and clinical roadmap, for NPs/dendrimers for the preclinical stage to commercialization. Ultimately, we raise the clinical translation of new nanomedicine issues.